153Sm: Its use in multiple myeloma and report of a clinical experience

Elisabetta Abruzzese, Francesco Iuliano, Malgorzata Monika Trawinska, Massimo Di Maio

Research output: Contribution to journalArticlepeer-review


Background: In the past years the bone seeking radiopharmaceutical samarium lexidronam (153Sm-EDTMP) has been increasingly used alone or in conjunction with chemotherapy and/or bisphosphonates for the treatment of painful bone metastasis. Objective: Its use has been explored in different solid tumours. In this report we explore its interesting characteristics and describe our experience in multiple myeloma (MM). Methods: 153Sm-EDTMP has an affinity for bone and concentrates in areas of bone turnover. It decays as a therapeutic β-emission and at the same time as γ-photon that can be used for tracking its concentration with bone scan imaging. Ten patients with symptomatic MM were treated to achieve pain control. Results: Encouraging results were obtained in MM patients. The use of this radioisotope could be largely improved.

Original languageEnglish
Pages (from-to)1379-1387
Number of pages9
JournalExpert Opinion on Investigational Drugs
Issue number9
Publication statusPublished - Sep 2008


  • Sm
  • Bone metastasis
  • Multiple myeloma
  • Radiopharmaceutical

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of '153Sm: Its use in multiple myeloma and report of a clinical experience'. Together they form a unique fingerprint.

Cite this